Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products
Comments Off on Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products
June 22, 2026
The DEA rescheduling Schedule III cannabis marks a pivotal regulatory change for FDA approved cannabis products. This shift facilitates improved medical cannabis access under federal law. Clinicians and patients should understand the implications of this…
FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule
Comments Off on FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule
June 9, 2026
The U.S. Department of Justice has proposed rescheduling FDA-approved cannabis-derived products from Schedule I to Schedule III, recognizing their medical utility while maintaining controlled substance oversight. This cannabis schedule III…
Federal Marijuana Rescheduling to Schedule III: What It Means for Your Practice and Patients
Comments Off on Federal Marijuana Rescheduling to Schedule III: What It Means for Your Practice and Patients
April 27, 2026
Schedule III cannabis clinical practice has formally arrived. On April 23, 2026, the Justice Department placed FDA-approved marijuana products and state-regulated medical cannabis in Schedule III, with an expedited hearing June 29 to consider full…